CATX

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

SEATTLE, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the U.S. Food and Drug Administration (the "FDA") granted Fast Track Designation for the development of PSV359 for adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein (FAP)-positive solitary fibrous tumors (SFTs). SFT is a rare cancer for which patients with locally advanced unresectable or metastatic disease have limited treatment options. [²¹²Pb]PSV359 is an investigational FAP

SEATTLE, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that data from the Company’s [²¹²Pb]VMT-α-NET program have been accepted for presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium taking place November 5 to 7, 2026, in Las Vegas, Nevada. Presenter Abstract TitlePresentation DetailsThorvardur Halfdanarson, MD, Mayo Clinic RochesterCohort level safety and efficacy results for [212Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroen

SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that data from the Company’s lapemelanotide zapixetar (also known as [²¹²Pb]VMT01) program have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting & Pre-Conference Programs taking place November 4 to 8, 2026, in Phoenix, Arizona. SITC plans to release further details for regular abstracts on November 3, 2026. Presenting AuthorAbstract TitlePresentation DetailsMatthew Block, Departme

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

William Blair initiated coverage of Perspective Therapeutics with a rating of Outperform

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE:MRK), known as MSD outside of the United States and Canada. The agreement supports the evaluation of Perspective’s targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda® (pembrolizumab), Merck’s anti-PD-1 therapy. This combination will be evaluated under an amendment to the Company’s ongoing Phase 1/2a study of [212Pb]PSV359 in patients with certain t

SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the 38th EORTC-NCI-AACR (ENA) Symposium 2026 on Molecular Targets and Cancer Therapeutics taking place November 18 to 20, 2026 in Barcelona, Spain. The conference plans to release further details for abstracts on November 4, 2026. PresenterAbstract TitlePresentation DetailsVikas Prasad, Washington University School

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

BMO Capital Markets initiated coverage of Perspective Therapeutics with a rating of Outperform and set a new price target of $11.00

10-Q - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback; sufficient isotope access and manufacturing capacityVMT-α-NET study update accepted for oral presentation at ESMO 2026VMT01 melanoma and PSV359 FAP-α clinical programs continue to advanceApproximately $237 million in cash, cash equivalents, and short-term investments as of June 30, 2026; expected to be sufficient to fund current planned clinical milestones and operational investments into late 2027 SEATTLE, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (

SCHEDULE 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

SEATTLE, July 31, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2026 financial results and provide a business update on Monday, August 10, 2026 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases. About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throu

European orphan medicinal product designation granted for [²¹²Pb]VMT-α-NET for the treatment of GEP-NETs[²¹²Pb]VMT-α-NET is being evaluated in an ongoing Phase 1/2a study in patients with SSTR2-positive neuroendocrine tumors; interim clinical data support [212Pb]VMT-α-NET’s potential to provide significant benefit relative to approved therapies for European patients living with GEP-NETs Designation provides development and potential commercial incentives to support the advancement of [²¹²Pb]VMT-α-NET in Europe SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development com

SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026. PresenterAbstract TitlePresentation DetailsThorvardur Halfdanarson, Mayo Clinic Comprehensive Cancer CenterCohort level s

SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Paul Lyne, Ph.D., as Chief Science Officer. The Company also announced that Michael K. Schultz, Ph.D., co-founder and the Company’s long-time Chief Science Officer, has transitioned to the role of Senior Scientific Advisor & Co-Founder as part of a planned transition toward retirement. "It is impossible to overstate the impact Michael Schultz has had on Perspective," said Thijs Spoor, Perspective’s CEO. "Togeth

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the first meningioma patient was dosed with [212Pb]VMT-α-NET in the Company's ongoing Phase 1/2a study. The new cohort is intended to evaluate the safety, dosimetry, and preliminary anti-tumor activity of lead-based alpha-particle therapy with [212Pb]VMT-α-NET for meningioma (LEMONαDE). The initiation of the meningioma cohort reflects The Company's broader strategy to evaluate [212Pb]VMT-α-NET across somatostatin receptor su

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were consistent with previously disclosed findings at AACR as of March 4, 2026 with continued deepening